Matinas BioPharma Holdings (MTNB) Income from Continuing Operations (2014 - 2026)
Matinas BioPharma Holdings (MTNB) reported Income from Continuing Operations of 1936000.0 for Q1 2026, up 0.51% year-over-year from 1926102.25 in Q1 2025, and down 21.0% quarter-over-quarter from 1600000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 13 years of Income from Continuing Operations data on file, last reported at 1936000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 1936000.0, up 0.51% year-over-year; the trailing twelve-month figure through Mar 2026 was 6950000.0 (up 66.32% YoY), and the FY2025 annual result was 10345000.0, up 57.34% from the prior year.
- Income from Continuing Operations fell to 1936000.0 in Q1 2026 per MTNB's latest filing, from 1600000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1577000.0 in Q3 2025 and troughed at 8469000.0 in Q4 2024.
- A 5-year average of 4814235.29 and a median of 5586000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 43.86% in 2024, then jumped 81.11% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 5480000.0 in 2022, then declined by 7.43% to 5887000.0 in 2023, then plunged by 43.86% to 8469000.0 in 2024, then jumped by 81.11% to 1600000.0 in 2025, then declined by 21.0% to 1936000.0 in 2026.
- Business Quant data shows MTNB's Income from Continuing Operations at 1936000.0 in Q1 2026, 1600000.0 in Q4 2025, and 1577000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | -1.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.94 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Sep 30, 2025 | -1.58 Mn |
| Jun 30, 2025 | -1.84 Mn |
| Mar 31, 2025 | -1.95 Mn |
| Dec 31, 2024 | -8.47 Mn |
| Sep 30, 2024 | -4.38 Mn |
| Jun 30, 2024 | -5.84 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Dec 31, 2023 | -5.89 Mn |
| Sep 30, 2023 | -6.13 Mn |
| Jun 30, 2023 | -6.16 Mn |
| Mar 31, 2023 | -5.59 Mn |
| Dec 31, 2022 | -5.48 Mn |
| Sep 30, 2022 | -5.46 Mn |
| Jun 30, 2022 | -5.93 Mn |
| Mar 31, 2022 | -7.72 Mn |
| Dec 31, 2021 | -6.71 Mn |
| Sep 30, 2021 | -6.88 Mn |
| Jun 30, 2021 | -4.79 Mn |